(S035) Validity of Current Stereotactic Body Radiation Therapy (SBRT) Dose Constraints for Aorta and Major Vessels

Publication
Article
OncologyOncology Vol 30 No 4_Suppl_1
Volume 30
Issue 4_Suppl_1

From logistic modeling of 625 major vessels, the Radiation Therapy Oncology Group 0813 trial limit of Dmax = 52.5 Gy in five fractions was found to have a 1.2% risk of grade 3–5 toxicity, and the 2008 Timmerman limit of Dmax = 45 Gy in three fractions had a 2.3% risk. Further investigation is warranted, especially for the pulmonary artery, which might not have a dose tolerance as high as other major vessels.

Jinyu Xue, PhD, Gregory Kubicek, MD, Ashish Patel, MD, Benjamin Goldsmith, MD, Tamara LaCouture, MD, Sucha Asbell, MD; UT MD Anderson Cancer Center at Cooper University Hospital

PURPOSE: Major blood vessel toxicity data from stereotactic body radiation therapy (SBRT) are particularly sparse. Therefore, we investigated aorta and major vessel dose-response models to determine tolerance in patients treated with 1 to 5 fractions.

METHODOLOGY: A total of 625 major vessel structures, including aorta, vena cava, pulmonary artery, and pulmonary vein, were analyzed via dose-volume histograms (DVHs). From July 2008 to February 2015, a total of 387 cases with major vessels exposed to 1 to 5 fractions of SBRT with CyberKnife (Accuray, Inc., Palo Alto, CA) in our institution were studied. These data were combined with DVH data on 238 major vessels from the 2014 Nishimura study (J Thorac Oncol 2014;9:1370–6). The median number of fractions was 5, so the linear quadratic model with alpha/beta = 3 Gy was used to convert all doses to 5-fraction equivalent doses prior to any other modeling. DVH Evaluator software (DiversiLabs, LLC, Huntingdon Valley, PA) was utilized to create a logistic dose-response model of the aggregate dataset using maximum likelihood parameter fitting.

RESULTS: The published dataset included three Common Terminology Criteria for Adverse Events version 4 grade 3–5 pulmonary artery complications, and there were no observable major vessel complications in our dataset. The logistic model TD50 for Dmax was 81 Gy, and the slope parameter was 3.13. Models for V25Gy, D4cc, D1cc, and D0.5cc will also be presented. When the 73 pulmonary artery contours from Nishimura (2014) were analyzed alone, the risk was increased by approximately fivefold, but it is not known whether this was due to intrinsically increased sensitivity or attributable to lack of data in the omission of 552 noncomplication data points.

CONCLUSIONS: From logistic modeling of 625 major vessels, the Radiation Therapy Oncology Group 0813 trial limit of Dmax = 52.5 Gy in five fractions was found to have a 1.2% risk of grade 3–5 toxicity, and the 2008 Timmerman limit of Dmax = 45 Gy in three fractions had a 2.3% risk. Further investigation is warranted, especially for the pulmonary artery, which might not have a dose tolerance as high as other major vessels.

Proceedings of the 98th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) A 15-Year Review of Radiation Therapy for Keloids at Two Institutions
(S003) Single-Fraction Radiation Therapy for the Treatment of Multiple Myeloma Bony Metastases Provides Pain Control and Decreases Time to Chemotherapy
(S001) Prognostic Value of Pretreatment Serum Inflammatory Markers in Patients Receiving Radiation Therapy for Oropharyngeal Cancer
(S004) Trend in Second Malignancy Risk for Head and Neck Cancer With Increased Utilization of IMRT: Analysis of SEER Database
(S005) Comparison of Legal Needs of a Group of Patients With Cancer: Economic and Geographic Factors
(S006) Mission Improvement: Lessons From Initiating a Resident-Led Quality Improvement Project on Smoking Cessation at a County Hospital
(S007) Results of a Phase II Trial Using Cetuximab Plus Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
(S008) The Effect of Simulation and Treatment Delays for Patients With Oropharyngeal Cancer Receiving Definitive Radiation Therapy in the Era of Risk Stratification Using Smoking and Human Papilloma Virus Status
(S009) Intensity-Modulated Radiation Therapy With Stereotactic Body Radiation Therapy Boost for Unfavorable Prostate Cancer: A Report on Three-Year Toxicity
(S011) Comparative Study Between Ileal Conduit and Indiana Pouch After Cystectomy for Patients With Carcinoma of Urinary Bladder
(S010) Computed Tomography–Assessed Measures of Bone Mineral Density and Muscle Mass as Predictors of Survival in Men With Prostate Cancer
(S012) Quantitative Imaging to Evaluate the Malignant Potential of Pancreatic Cysts
(S013) Spine Stereotactic Radiosurgery With Concurrent Tyrosine Kinase Inhibitors for Metastatic Renal Cell Carcinoma
(S014) The Impact of Radiation Therapy on Survival in Surgically Resected, High-Risk Patients With Ampullary Adenocarcinoma: A Population-Based Analysis
(S016) The Impact of Stereotactic Body Radiation Therapy on Overall Survival in Patients With Locally Advanced Pancreatic Cancer
Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Optimal cancer survivorship care may entail collaboration between a treating oncologist and a cancer survivorship expert.
Related Content